Quadrant buy focuses ML Labs firmly on pulmonary delivery
This article was originally published in Clinica
Executive Summary
UK group ML Laboratories has agreed to pay $46.7m ($85m) for Nottingham-based Quadrant Technologies, which specialises in formulating drugs for inhalation.